Glypican-3 (GPC3) expression in hepatocellular carcinoma (HCC) is often associated with a poor prognosis. GPC3 is a promising target for tumor-specific immunotherapy in HCC. We investigated the diagnostic performance of viscoelastic properties quantified by tomoelastography, a multifrequency MR-elastography (MRE) technique, for the detection of GPC3-positive HCC. Preliminary results showed that reduced stiffness quantified by tomoelastography is a mechanical signature of positive GPC3 expression in HCC. Combining stiffness and serum alpha-fetoprotein (AFP) level could be considered as a viable biomarker for detecting GPC3-positive HCC as well as for predicting the outcome of GPC3-targeted immunotherapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords